Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Reconsidering Drug Chains' Divestiture Strategies - Commission's Balto

This article was originally published in The Rose Sheet

Executive Summary

The Federal Trade Commission is reconsidering its traditional strategy of requiring the divestiture of store locations before approving drug chain mergers, FTC Bureau of Competition Office of Policy and Evaluation Assistant Director David Balto told the National Association of Chain Drug Stores Aug. 31.

You may also be interested in...



FTC Public Workshop On Retail Slotting Issues Urged By Senate Committee

A Federal Trade Commission public workshop to discuss the practice of slotting in retail outlets is suggested by the Senate Committee on Small Business in an Oct. 20 letter to the commission.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel